When you purchase through links on our site , we may earn an affiliate commissioning . Here ’s how it works .
An sovereign mathematical group of medical experts in the U.S. has raised concerns that AstraZeneca may have released " superannuated " data on its COVID-19 vaccine .
AstraZenecaannouncedon Monday ( March 22 ) that its coronavirus vaccinum was 79 % effectual at forbid symptomatic COVID-19 and 100 % effective at preclude life-threatening or critical illness and hospitalization in a belated - stage trial conducted in the U.S. that demand more than 32,000 volunteers .
Related : Quick templet : COVID-19 vaccines in use and how they work
The NIAID urge the company to work with the data and safety monitoring plank to " reexamine the efficaciousness data and ensure the most precise , up - to - date efficacy data point be made public as quickly as possible . " On Tuesday , AstraZenecareleased a statementin reply to NIAID saying that the numbers they released in a press release on Monday were base on a " pre - specified " interim analysis that had a data cutoff of Feb. 17 . ( An interim analysis is a preliminary analysis that analyzes information from an on-going test before that trial is completed . )
— 11 ( sometimes ) deadly disease that hop-skip across species
— 14 coronavirus myths rupture by scientific discipline
— The 12 mortal virus on Earth
" We have reviewed the preliminary judgement of the main psychoanalysis and the results were consistent with the interim analysis , " they wrote . " We will immediately engage with the independent data safety monitoring table ( DSMB ) to share our primary analysis with the most up to date efficacy data . " They add that they intend to issue the results of the elementary analysis within 48 hours .
The AstraZeneca vaccinum has not yet been approved for emergency use in the U.S. , but it has been approved in various other countries .
The company ’s COVID-19 vaccinum has come under examination after a telephone number of countries in Europe , include Germany , France , Italy and Spain , stopped or paused the AstraZeneca vaccine rollout over concern of possible links to blood clots .
After an investigation , the European Union ’s European Medicines Agency conclude on March 18 that the AstraZeneca vaccinum is safe and effective , even though the rarefied peril of origin clots could not be completely ruled out , Live Science antecedently report .
Originally release on Live Science .
